TABULOSE® SC - Colloidal microcrystalline cellulose

This excipient is used as filler for gelatin capsules and binder for direct compression. LYCATAB® C and C-LM combines the disintegration power of starch grains with the high cohesion and good compressibility.

Partially hydrolyzed starch for solid dosage forms, used as a binder for wet granulation and as diluent for direct compression.

Natural pregelatinized starch LYCATAB® PGS: solid dosage forms. This excipient is used as a binder for wet granulation.

Roquette’s LYCOAT® range is a major breakthrough in aqueous film coating and film forming.

Native starches of plant origins : Maize, wheat and potato. Extra white maize starch has a disintegration function and can be used as insoluble diluents.

Delivering secure supply with the right partner. Trust is the most essential ingredient.

White to yellow powders food ingredient obtained from maize tapioca and potato starch by heat treatment. Ingredients for clinical nutrition & nutraceuticals.

KLEPTOSE® HPB-LB is a hydroxypropyl beta-cyclodextrin parenteral grade material that is used as an encapsulating agent for Rx injectables. It is a modified betacyclodextrin for parenteral use.

Precision Dispense helps you streamline complex Biopharmaceutical workflows to bring valuable drug products to market quickly and safely.

Discover how we can help you Roquette as a technology partner and a trusted supplier, provides scientists and researchers with a collaboration platform to beter understand and formulate with our ingredients. Innovation Hub | Roquette Pharma Solutions

LYCAGEL® VS 720 hydroxypropyl pea starch. It offers excellent film-forming properties for the manufacture of veggie soft capsules in both pharmaceutical and nutraceutical applications.

The new facility will focus on the research of excipients for oral dosage forms, drug delivery systems, nutraceutical APIs and innovative pharma ingredients

Discover the wide range of products by Roquette in Pharmaceuticals and Neutraceuticals

The ramping up of vaccine manufacturing demand amid the COVID-19 pandemic had an initial impact on cell and gene therapy production but the regenerative medicine sector has largely weathered the storm, according to senior industry figures in a recent panel discussion at the CPHI Festival of Pharma virtual event.